Incorporating Immunotherapy in the Treatment of Hodgkin Lymphoma

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.

Release Date: May 19, 2017
Expiration Date: May 19, 2018

Expected time to complete this activity as designed: 45 minutes
There are no fees for participating in or receiving credit for this online activity.

Program Overview

The approval of nivolumab in May of 2016 for patients with classical Hodgkin lymphoma (HL) that has relapsed or progressed after autologous stem cell transplant and post-transplantation brentuximab vedotin, represented the first checkpoint inhibitor in HL. The unique features of checkpoint inhibitors, including immune-mediated adverse events and the possibility of non-traditional response patterns, may create a challenge in using these agents in practice. In this activity, Dr. Moskowitz will discuss the clinical profiles of recently approved immunotherapeutic agents, as they relate to HL, focusing on practical strategies for treatment and management of patients in practice, as well as on the safety and efficacy profiles of each.

Target Audience

This activity is designed for physicians, pharmacists, physician assistants, and other health care professionals who have an interest in enhancing their clinical skills in Hodgkin lymphoma.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Summarize the potential role of immunotherapy in the treatment of HL
  • Outline the efficacy and safety of cancer immunotherapies studied in clinical trials for patients with relapsed/refractory HL


Incorporating Immunotherapy in the Treatment of Hodgkin Lymphoma – Craig Moskowitz, MD

Instructions for Participation and Credit

This activity is eligible for credit through May 19, 2018. After this date, this activity will expire and no further credit will be awarded.

  1. Read the target audience, learning objectives, and faculty disclosures.
  2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
  3. Complete the educational content as designed.
  4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
  5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
  6. Certificates for CME may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biography

Craig Moskowitz, MD
Steven A. Greenberg Chair in Lymphoma Research
Professor of Medicine
Cornell University Medical College
New York, New York

Dr. Craig Moskowitz received his medical degree from Wayne State University School of Medicine in Detroit. He completed his residency in internal medicine and served as chief resident, he then completed a fellowship in hematology/oncology at Memorial Sloan Kettering Cancer Center (MSKCC) and served as the chief fellow. Dr. Moskowitz is currently the Steven A. Greenberg Chair in Lymphoma Research. He is also a member at Memorial Sloan Kettering Cancer Center, attending physician on the Lymphoma and Adult Bone Marrow Transplant Services, and a Professor of Medicine at Cornell University Medical College.

Dr. Moskowitz serves as principal investigator and co-investigator for a number of clinical trials aimed at improving the care of patients with lymphoma. His research has focused on improving the outcome of patients with poor-risk diffuse large B-cell lymphoma (DLBCL) and Hodgkin lymphoma (HL). This effort has been conducted along two tracks. One effort is focused on improving therapy for patients with disease that has returned or is not responding to standard therapy (refractory disease) through the use of high-dose therapy and autologous stem cell transplantation, as well as new agents that can be incorporated into such "salvage" therapy. The second is aimed at evaluating antibody drug conjugates and checkpoint inhibitors in the chronic lymphoma patient population with the hope of moving these treatments to the upfront setting.

Dr. Moskowitz has been recognized for his research on a national level through multiple awards. He has lectured worldwide on lymphoma and stem cell transplantation. In addition, he is the Chair of Research Council at MSKCC, and on the steering committees for the International Conference on Malignant Lymphoma in Lugano, Switzerland, the International Symposium on Hodgkin Lymphoma (ISHL) in Cologne, Germany, and the NCCN Hodgkin Lymphoma Panel.


Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of .75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.75 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-17-140-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.


As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosure

Dr. Craig Moskowitz has received honoraria as a consultant from Celgene Corporation, Genentech BioOncology, Merck & Co., Inc., and Seattle Genetics, Inc. He has received grant support related to research activities from Merck, Pharmacyclics, Inc., and Seattle Genetics.

Planning Committee Disclosures

The individual listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, Executive Director, has no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Merck & Co., Inc., Seattle Genetics, and Takeda Oncology.

©2017 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.

Managing HL would like to recognize and thank Bristol-Myers Squibb, Merck & Co., Inc., and Seattle Genetics for their educational support of in 2018.

©2019 MediCom Worldwide, Inc. All rights reserved